Pedro Beltran
Bridge Bio, Palo Alto, USA
Pedro is currently the Head of Biology at BridgeBio Oncology Therapeutics (BBOT) in South San Francisco, California. Pedro and the Team of experienced drug hunters at BBOT are dedicated to developing novel therapeutics to target RAS, the most frequently mutated human oncogene. In collaboration with Frederick (FNL) and Lawrence Livermore (LLNL) National Laboratories, the BBOT Team is focused on targeting the active form of KRAS (KRAS-GTP) as well as the activation of PIK3CA by RAS family members. Pedro received a B.S. in Molecular Biology from Florida Tech and a Ph.D. in Cancer Biology from the University of Texas, M.D. Anderson Cancer Center under the mentorship of Isaiah J. Fidler, DVM, Ph.D. He was awarded a Lois Pope Fellowship for post-doctoral work in Neuroscience at the Miami Project to Cure Paralysis, University of Miami. Pedro has a long track-record of dedication to the discovery of novel medicines to treat serious illnesses. Prior to BridgeBio Pharma, Pedro led the Biology Team at UNITY Biotechnology, a company dedicated to preventing, halting, and reversing diseases of aging. His Team’s work resulted in the identification of UBX1325, a potential novel treatment for vascular eye diseases that has demonstrated exciting efficacy in Phase 2 clinical trials. Pedro started his career as a Scientist at Amgen Inc. where he led multiple Pharmacology Research Programs in Oncology including Imlygic® for melanoma and ganitumab for pancreatic cancer. As Executive Director of Discovery Research at Amgen, he led a large team of Scientists and helped progress more than 10, diverse modality, development candidates into the clinic. Pedro believes in a strong industry-academic partnership as a viable path for drug discovery and has a long history of supporting productive collaborations with leading academic groups in oncology and aging. Pedro has authored more than 40 peer-reviewed manuscripts and abstracts. He has been an invited speaker in multiple national and international conferences and holds patents describing novel ways to treat malignant disease.
Pedro is currently the Head of Biology at BridgeBio Oncology Therapeutics (BBOT) in South San Francisco, California. Pedro and the Team of experienced drug hunters at BBOT are dedicated to developing novel therapeutics to target RAS, the most frequently mutated human oncogene. In collaboration with Frederick (FNL) and Lawrence Livermore (LLNL) National Laboratories, the BBOT Team is focused on targeting the active form of KRAS (KRAS-GTP) as well as the activation of PIK3CA by RAS family members. Pedro received a B.S. in Molecular Biology from Florida Tech and a Ph.D. in Cancer Biology from the University of Texas, M.D. Anderson Cancer Center under the mentorship of Isaiah J. Fidler, DVM, Ph.D. He was awarded a Lois Pope Fellowship for post-doctoral work in Neuroscience at the Miami Project to Cure Paralysis, University of Miami. Pedro has a long track-record of dedication to the discovery of novel medicines to treat serious illnesses. Prior to BridgeBio Pharma, Pedro led the Biology Team at UNITY Biotechnology, a company dedicated to preventing, halting, and reversing diseases of aging. His Team’s work resulted in the identification of UBX1325, a potential novel treatment for vascular eye diseases that has demonstrated exciting efficacy in Phase 2 clinical trials. Pedro started his career as a Scientist at Amgen Inc. where he led multiple Pharmacology Research Programs in Oncology including Imlygic® for melanoma and ganitumab for pancreatic cancer. As Executive Director of Discovery Research at Amgen, he led a large team of Scientists and helped progress more than 10, diverse modality, development candidates into the clinic. Pedro believes in a strong industry-academic partnership as a viable path for drug discovery and has a long history of supporting productive collaborations with leading academic groups in oncology and aging. Pedro has authored more than 40 peer-reviewed manuscripts and abstracts. He has been an invited speaker in multiple national and international conferences and holds patents describing novel ways to treat malignant disease.
